IQV · IQVIA Holdings Inc.

Healthcare NYQ United States iqvia.com ↗
Val Gro Qua Mom Sta Cap P/S2.54 P/E Fwd P/E18.10 PEG0.93 52W –  RSI Target$276.28 (+5.5%) Beta1.19 Div
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Diagnostics & Research Durham, United States 94,000 employees
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 60 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
8Bullish
5Bearish
0Neutral

Key Signals 2

▲ Double Bottom Major reversal 2026-06-26 · $190.68
Two lows ~$161.99 — bullish reversal confirmed
Learn more →
▲ Double Bottom Major reversal 2026-08-19 · $245.3
Two lows ~$230.45 — bullish reversal confirmed
Learn more →

Momentum Signals 11

▲ MACD Bullish Crossover 2026-05-28 · $181.09
▲ MACD Bullish Crossover 2026-06-26 · $191.14
▲ MACD Bullish Crossover 2026-07-28 · $242.94
▲ Bull Flag 2026-08-07 · $238.49

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Nov 03, 2026
Beat Rate 100%
Consensus STRONG BUY
Analyst Upside +5.5%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
STRONG BUY
18
3
BuyHoldSell
Price Target Range
$276.28 +5.5% upside
Low $240 High $300
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 32.97%Last 12 Months
Operating Margin 13.03%Last 12 Months
Return on Equity 22.82%Last 12 Months
Revenue Growth 8.70%Year over Year
Free Cash Flow 2.15BLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 257.98Most Recent Quarter
Current Ratio 0.71Most Recent Quarter
Cash 2.08BMost Recent Quarter
Total Debt 16.25BMost Recent Quarter
Net Debt Most Recent Quarter
How IQV Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap43.09B
Enterprise Value57.39B
Trailing P/E32.60
Forward P/E18.10
PEG Ratio (5yr)0.93
Price/Sales (ttm)2.54
Price/Book (mrq)6.98
EV/Revenue3.38
EV/EBITDA18.83
Share Statistics
Avg Vol (3m)1.44M
Shares Outstanding164.60M
Float156.25M
% Held by Insiders1.09%
% Held by Institutions103.42%
Short Ratio3.00
Short % of Float2.66%
Profitability
Gross Margin32.97%
Operating Margin (ttm)13.03%
Profit Margin8.10%
Return on Assets (ttm)5.06%
Return on Equity (ttm)22.82%
Income Statement
Revenue (ttm)16.98B
Revenue Growth (yoy)8.70%
Gross Profit (ttm)5.60B
EBITDA3.05B
Net Income (ttm)1.38B
Diluted EPS (ttm)8.03
EPS Growth (yoy)-0.60%
Balance Sheet
Total Cash (mrq)2.08B
Total Debt (mrq)16.25B
Debt / Equity (mrq)257.98
Current Ratio (mrq)0.71
Book Value / Share37.49
Operating CF (ttm)2.82B
Free Cash Flow (ttm)2.15B
Trading & Dividends
Beta (5Y)1.19
50-Day MA234.05
200-Day MA202.50
Fwd Dividend YieldN/A
Payout Ratio0.00%

No dividend history available for IQV.

Ownership Breakdown
Institutional 103.42% Insider 1.09%
Short Interest 2.66% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in IQV in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value